Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3979485 | Bulletin du Cancer | 2010 | 12 Pages |
Abstract
Cyberknife® (Accuray Inc. Sunnyvale, USA) stereotactic body radiation therapy (SBRT) involves the delivery of a small number of large doses of radiation to a target volume using continuously evolving advanced technology. It has emerged as a novel treatment modality for cancer and modified some concepts of cancer treatment. It is indicated in early-stage primary cancer, sometimes as an alternative to surgery. It is also indicated for patients with oligometastatic disease who have relatively long survival with the aim to optimize disease control with a good quality of life. Although there remain some uncertainties regarding the radiobiology of hypofractionation, local control and tolerance have been promising. Indications are increasing under strict quality assurance programs worldwide and prospective clinical evaluation.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J. Thariat, S. Marcié, P.-Y. Marcy, R. Trimaud, G. Angellier, H. Mammar, P.-Y. Bondiau, J.-P. Gerard,